Last reviewed · How we verify
NCT01435629
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
trial testing somatropin in Genetic Disorder in 81 participants. Completed in 4 December 2015.
4 December 2015
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 81 |
| Start date | 22 November 2012 |
| Primary completion | 4 December 2015 |
| Estimated completion | 4 December 2015 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- somatropin (Somatropin) — full drug profile →
Conditions studied
- Genetic Disorder — all drugs for Genetic Disorder →
- Achondroplasia — all drugs for Achondroplasia →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Genetic Disorder or Achondroplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01435629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of somatropin
Trials testing the same drug.
- NCT02726542 — Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents · EARLY_PHASE1 · completed
- NCT02382939 — A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Prev · Phase 3 · completed
- NCT02229851 — Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropi · Phase 3 · completed
- NCT02092077 — A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children · Phase 2 · terminated
- NCT01973244 — A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth · Phase 1 · completed
Other recruiting trials for Genetic Disorder
Currently open trials in the same condition.
- NCT04743466 — Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes · active not recruiting
- NCT05212428 — DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study · NA · active not recruiting
- NCT06898307 — Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: · recruiting
- NCT06362473 — Lipid Transport Disorder Italian Genetic Record (LIPIGEN) · recruiting
- NCT01851447 — Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy · active not recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01435629 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 5 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01435629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing